While news about vaccines is mostly dominated by COVID-19 right now, work is continuing to find a vaccine that can protect against different types of cancer. The latest development comes from Anixa Biosciences (ANIX:NASDAQ) and Cleveland Clinic, which has developed a breast cancer vaccine that could stop this deadly disease in its tracks.
After being in development for over a decade, the team has been given FDA approval to begin human trials, following a 100% success rate in animal trials. With breast cancer being the most common type of cancer in women worldwide, this news could have a positive outcome in the fight against the disease, as well as other types of cancer.
Breast cancer rates continue to grow worldwide
Breast cancer rates are continuing to grow, with more than 2 million cases reported every year. Survival rates have continued to improve over the years, with the five-year survival rate for a stage 1 or 2 breast cancer diagnosis being 80% and 90% in some parts of the world.
Work is ongoing to develop new treatments and a potential cure, whereas another approach has been to develop a vaccine that could prevent cancer from developing in the first place.